APR 10, 2018 5:24 PM PDT

'Melting Away' Chronic Lymphocytic Leukemia (CLL)

WRITTEN BY: Nouran Amin

Chronic lymphocytic leukemia (CLL) is a form of cancer that that first occurs in the cells that become certain white blood cells (called lymphocytes) which present in the bone marrow, later the cancer spreads to the blood.

In CLL, the leukemic cells progress very slowly and many individuals don't appear to have any symptoms for at least a few years. However, as the cancer continues to progress, the cells may reach other parts of the body, including the lymph nodes, liver, and spleen.A new oncology drug, Venetoclax, which was developed to treat two types of blood cancer now holds the potential to replace chemotherapy according to lead researcher John Seymour from the Peter MacCallum Cancer Centre (PMCC) in Victoria, Australia

In a large clinical trial, 389 patients across 20 countries diagnosed with chronic lymphocytic leukemia (CLL) and who had previously been treated and then relapsed were given venetoclax in combination with a standard immunotherapy drug known as rituximab, or just rituximab on its own. The results of the clinical study showed that for at least 15 months, 78% of patients after the treatment.

When a patient relapses, CLL is untreatable. However, during the clinical trial, nearly 85% the patients who were treated with venetoclax in combination with rituximab were measured to have a few to non-detectable leukemic cells in comparison to just 36% of those patients who received the standard immunotherapeutic. “That venetoclax is able to produce such dramatic results in this hard-to-treat patient group is remarkable and has led to much excitement among blood cancer clinicians globally and the research community particularly in Melbourne where this drug was pioneered,” says Seymour. “The data shows venetoclax should replace chemotherapy altogether in patients with advanced forms of CLL—a practice-changing result which will rapidly translate into the standard of care globally.”

High-power magnification (1000x) of a blood smear showing chronic lymphocytic leukemia. Image Source: MARY ANN THOMPSON/WIKIMEDIA

During a second clinical trial, by PMCCC lead researcher Constantine Tam, venetoclax was given to previously treated and relapsed Mantle Cell lymphoma (MCL) patients in combination with the immunotherapeutic ibrutinib.

Similar to CLL, there is no cure for relapsed MCL patients. However, it is important to note that MCL is more rare and aggressive than CLL. “It’s unprecedented that we’re seeing such deep responses in a such a high proportion of patients. These drugs will almost certainly replace chemotherapy going forward. It could be game-changing if these responses are durable,” says Sunil Iyengar, who wasn't involved in the studies but a consultant hemato-oncologist at the Royal Marsden NHS Foundation Trust in the U.K.

The development of Venetoclax was based on a landmark discovery by investigators at the Walter and Eliza Hall Institute in Melbourne. The discovery was a protein now called BCL-2 that works to promote the survival of cancerous cells.

“Venetoclax selectively targets BCL-2, essentially causing cancerous cells to simply melt away, in many instances,” says clinical haematologist, Andrew Roberts researcher at Walter and Eliza Hall Institute.

Sources: The New England Journal of Medicine, Newsweek

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 06, 2020
Drug Discovery & Development
Anti-depressant Shows Promise in Treating Childhood Cancer
NOV 06, 2020
Anti-depressant Shows Promise in Treating Childhood Cancer
Researchers from Sweden and the US have found that a commonly prescribed antidepressant may help stop the growth of a ca ...
DEC 03, 2020
Drug Discovery & Development
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
DEC 03, 2020
Oregon to Create Advisory Board for Psilocybin Mushroom Therapy
Last month, Oregon became the first state in the US to legalize psilocybin mushrooms as a therapeutic treatment. Now, th ...
DEC 08, 2020
Drug Discovery & Development
Powerful Antibiotic Targets Mycobacterium
DEC 08, 2020
Powerful Antibiotic Targets Mycobacterium
Mycobacterium abscessus is a pathogenic bacterium know to cause tuberculosis and leprosy. Researchers at Johns Hopkins U ...
DEC 28, 2020
Cannabis Sciences
Does Cannabis Affect Stress in Men and Women Differently?
DEC 28, 2020
Does Cannabis Affect Stress in Men and Women Differently?
Researchers from Washington State University have found that cannabis may blunt the stress response differently in males ...
JAN 11, 2021
Cell & Molecular Biology
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
JAN 11, 2021
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
Naturally occurring chemicals make more appealing medicines for many people, but there is not always evidence that they' ...
JAN 02, 2021
Drug Discovery & Development
Drug Re-purposed for COVID-19
JAN 02, 2021
Drug Re-purposed for COVID-19
Pralatrexate, a chemotherapeutic drug originally developed to treat lymphoma, could be repurposed to treat COVID-19&mdas ...
Loading Comments...